|
1
|
BRAF mutation in metastatic colorectal cancer.
|
N Engl J Med
|
2009
|
3.68
|
|
2
|
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
|
Clin Cancer Res
|
2011
|
2.52
|
|
3
|
Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer.
|
Eur J Cancer
|
2012
|
1.73
|
|
4
|
Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
|
Eur J Cancer
|
2010
|
1.17
|
|
5
|
More is less -- combining targeted therapies in metastatic colorectal cancer.
|
Nat Rev Clin Oncol
|
2009
|
1.15
|
|
6
|
Setting future standards for KRAS testing in colorectal cancer.
|
Pharmacogenomics
|
2009
|
1.00
|
|
7
|
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
|
BMC Cancer
|
2012
|
0.92
|
|
8
|
Current issues in the targeted therapy of advanced colorectal cancer.
|
Discov Med
|
2010
|
0.83
|
|
9
|
Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.
|
Clin Colorectal Cancer
|
2008
|
0.80
|
|
10
|
Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
|
Anticancer Res
|
2011
|
0.79
|
|
11
|
Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.
|
Oncology
|
2017
|
0.75
|
|
12
|
A Specific Distress Cutoff Score Shortly After Breast Cancer Diagnosis.
|
Cancer Nurs
|
2016
|
0.75
|
|
13
|
Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus.
|
Int J Cancer
|
2014
|
0.75
|